CL2012001668A1 - Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros. - Google Patents

Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros.

Info

Publication number
CL2012001668A1
CL2012001668A1 CL2012001668A CL2012001668A CL2012001668A1 CL 2012001668 A1 CL2012001668 A1 CL 2012001668A1 CL 2012001668 A CL2012001668 A CL 2012001668A CL 2012001668 A CL2012001668 A CL 2012001668A CL 2012001668 A1 CL2012001668 A1 CL 2012001668A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
hydrochloric acid
epoc
ethanol
filling
Prior art date
Application number
CL2012001668A
Other languages
English (en)
Inventor
Sauro Bonelli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42046446&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001668(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of CL2012001668A1 publication Critical patent/CL2012001668A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
    • B65B31/06—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied the nozzle being arranged for insertion into, and withdrawal from, the mouth of a filled container and operating in conjunction with means for sealing the container mouth
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/10—Adding propellants in solid form to aerosol containers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición farmacéutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y un cosolvente, en donde la composición contiene ácido clorhídrico 1m en el intervalo de 0,005-1,0 ug/ul; kit que la comprende; y su uso para el tratamiento o la profilaxis de enfermedades respiratorias tal como epoc.
CL2012001668A 2009-12-23 2012-06-19 Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros. CL2012001668A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09015980 2009-12-23

Publications (1)

Publication Number Publication Date
CL2012001668A1 true CL2012001668A1 (es) 2012-12-07

Family

ID=42046446

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001668A CL2012001668A1 (es) 2009-12-23 2012-06-19 Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros.

Country Status (31)

Country Link
US (5) US20110150783A1 (es)
EP (1) EP2515854B1 (es)
JP (1) JP5800829B2 (es)
KR (1) KR101747474B1 (es)
CN (1) CN102665680B (es)
AU (2) AU2010334858A1 (es)
CA (1) CA2785317C (es)
CL (1) CL2012001668A1 (es)
CO (1) CO6551734A2 (es)
CY (1) CY1115109T1 (es)
DK (1) DK2515854T3 (es)
EA (1) EA021604B1 (es)
ES (1) ES2464520T3 (es)
GE (1) GEP20166479B (es)
HR (1) HRP20140550T1 (es)
IL (1) IL220534A0 (es)
MA (1) MA33821B1 (es)
MX (1) MX340264B (es)
MY (1) MY156950A (es)
NZ (1) NZ600789A (es)
PE (1) PE20121467A1 (es)
PH (1) PH12012501063A1 (es)
PL (1) PL2515854T3 (es)
PT (1) PT2515854E (es)
RS (1) RS53355B (es)
SG (1) SG181870A1 (es)
SI (1) SI2515854T1 (es)
TN (1) TN2012000261A1 (es)
UA (1) UA106098C2 (es)
WO (1) WO2011076842A2 (es)
ZA (1) ZA201204613B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160853A1 (es) 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
MX340264B (es) 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
HRP20180944T1 (hr) * 2013-12-30 2018-08-10 Chiesi Farmaceutici S.P.A. Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
BR112016014583B1 (pt) 2013-12-30 2022-12-20 Chiesi Farmaceutici S.P.A Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição
EP3701940B1 (en) 2015-12-04 2025-11-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN114515284A (zh) 2016-09-19 2022-05-20 墨西哥氟石股份公司 药物组合物
WO2020084549A1 (en) * 2018-10-25 2020-04-30 Glenmark Specialty S.A. Nebulization composition comprising glycopyrrolate and formoterol
AU2021314977B2 (en) 2020-07-31 2025-03-13 Chemo Research, S.L. Combination therapy for inhalation administration
CN112051346A (zh) * 2020-09-24 2020-12-08 珠海瑞思普利生物制药有限公司 一种同时测定茚达特罗和格隆溴铵含量的hplc方法
EP4225267A1 (en) 2020-10-09 2023-08-16 Chiesi Farmaceutici S.p.A. A pharmaceutical formulation for pressurised metered dose inhaler
MA61888B1 (fr) * 2021-07-09 2024-06-28 Astrazeneca Pharmaceuticals Lp Compositions, procédés et systèmes pour l'administration de médicament en aérosol
WO2023227781A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
EP0673240B1 (en) 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
EP1102579B1 (de) 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
JP5392880B2 (ja) * 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
ATE375142T1 (de) * 2001-03-30 2007-10-15 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
IL163843A0 (en) 2002-03-01 2005-12-18 Chiesi Farma Spa Formoterol superfine formulation
EP1575588A1 (en) 2002-12-16 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Tiotropium containing hfc solution formulations
DK1718336T3 (da) * 2004-02-06 2008-10-20 Meda Pharma Gmbh & Co Kg Ny kombination af anticholinergikum og beta-mimetika til behandling af luftvejssygdomme
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP2200550B1 (en) 2007-10-18 2018-04-18 Rose U, LLC Topical glycopyrrolate formulations
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
KR20120106753A (ko) * 2009-12-23 2012-09-26 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
BR112012015334A2 (pt) * 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
MX340264B (es) * 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
PE20160853A1 (es) * 2009-12-23 2016-09-14 Chiesi Farm Spa Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc)
EP3143987A1 (en) * 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
HRP20180944T1 (hr) * 2013-12-30 2018-08-10 Chiesi Farmaceutici S.P.A. Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola
BR112016014583B1 (pt) 2013-12-30 2022-12-20 Chiesi Farmaceutici S.P.A Composição de solução farmacêutica em aerossol, inalador pressurizado de dose calibrada e uso da dita composição

Also Published As

Publication number Publication date
ZA201204613B (en) 2013-09-25
CA2785317C (en) 2018-02-27
HRP20140550T1 (hr) 2014-07-18
US11590074B2 (en) 2023-02-28
AU2016234894B2 (en) 2018-02-22
EA021604B1 (ru) 2015-07-30
ES2464520T3 (es) 2014-06-03
EA201290374A1 (ru) 2013-01-30
US10806701B2 (en) 2020-10-20
WO2011076842A2 (en) 2011-06-30
MX2012006879A (es) 2012-07-04
AU2016234894A1 (en) 2016-10-13
TN2012000261A1 (en) 2013-12-12
PE20121467A1 (es) 2012-11-07
US20250262151A1 (en) 2025-08-21
WO2011076842A3 (en) 2011-12-01
CO6551734A2 (es) 2012-10-31
KR20120120160A (ko) 2012-11-01
US20230157951A1 (en) 2023-05-25
KR101747474B1 (ko) 2017-06-14
CN102665680B (zh) 2014-07-30
MY156950A (en) 2016-04-15
EP2515854B1 (en) 2014-03-19
CA2785317A1 (en) 2011-06-30
AU2010334858A1 (en) 2012-07-12
GEP20166479B (en) 2016-05-25
BR112012015336A2 (pt) 2016-03-15
EP2515854A2 (en) 2012-10-31
PL2515854T3 (pl) 2014-08-29
CN102665680A (zh) 2012-09-12
US12357568B2 (en) 2025-07-15
US20110150783A1 (en) 2011-06-23
MX340264B (es) 2016-07-04
SG181870A1 (en) 2012-07-30
CY1115109T1 (el) 2016-12-14
SI2515854T1 (sl) 2014-07-31
UA106098C2 (uk) 2014-07-25
PH12012501063A1 (en) 2013-02-04
JP2013515695A (ja) 2013-05-09
HK1174568A1 (en) 2013-06-14
US20150306026A1 (en) 2015-10-29
AU2016234894C1 (en) 2026-02-19
JP5800829B2 (ja) 2015-10-28
RS53355B (sr) 2014-10-31
DK2515854T3 (da) 2014-05-26
IL220534A0 (en) 2012-08-30
MA33821B1 (fr) 2012-12-03
NZ600789A (en) 2014-09-26
PT2515854E (pt) 2014-05-27
US20210000738A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CL2012001705A1 (es) Composición farmacéutica que comprende a) bromuro de glicopirronio, b) formoterol o fumarato de formoterol y c) dipropionato de beclometasona, disueltos en hfa134a y etanol (entre 10-15 % p/p), hcl 1m entre 0,15-0,28µg/µl; frasco; combinación farmaceútica; método para rellenar el frasco; y su uso en asma y/o epoc
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
TN2012000215A1 (en) Pharmaceutical compositions comprising a g l p -1 agonist and methionine
PE20141906A1 (es) Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
CL2012000469A1 (es) Composición farmacéutica que comprende un compuesto conjugado de insulina de absorcion lenta; un envase; una suspensión que comprende la composición y su método de preparación; su uso para el tratamiento o prevención de una patología asociado a deficiencia de insulina, como diabetes; un kit.
BR112014009031A2 (pt) formulações de etanercept estabilizadas com íons de metais
UA106098C2 (uk) Аерозольна композиція для хозл
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
PE20070951A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
MX2009008769A (es) Formulaciones de proteina que contienen sorbitol.
CL2009000309A1 (es) Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2.
PE20161132A1 (es) Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
HN2012000031A (es) Terapia de combinacion para el tratamiento de la diabetes
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
AR089302A1 (es) Un medicamento inhalable
CL2011002213A1 (es) Sal de adicion cristalina de (i) trometamina con (ii) un derivado de acido azabifenilaminobenzoico; composicion farmaceutica que comprende a la sal y otros agentes terapeuticos; combinacion farmaceutica; y su uso para el tratamiento de artritis reumatoide, artritis psoriasica, espondilitis anquilosante, esclerosis multiple, entre otras
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
UA111821C2 (uk) Застосування діатомітової землі як наповнювача у твердих фармацевтичних препаратах
GB201014391D0 (en) Drug composition and its use in therapy
CL2011001777A1 (es) Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares.
CL2013002353A1 (es) Uso de una composicion farmaceutica que contiene al menos un compuesto que contiene selenita y al menos un acido farmaceuticamente aceptable, util en la preparacion de un medicamento para el tratamiento de alteraciones celulares cervicales que tienen una calificacion pap de pap iii o pap iiid y/o una calificacion cin > o = a cin 1.
CO6551744A2 (es) Combinación de fármacos con teobromina y su uso en terapia